January 2024 in “Journal of medical clinical case reports” NX35growth™ effectively promotes hair growth and improves hair health.
October 2023 in “Bioactive Materials” The new hair loss treatment combining nitric oxide and minoxidil in a special carrier is effective for hair regrowth.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
January 2016 in “Jurnal Farmasi Indonesia” The 10% hibiscus leaf extract hair tonic promotes better hair growth than 2% minoxidil but causes eye irritation.
9 citations
,
June 2021 in “Journal of Inflammation Research” Euph E and Euri A from Euphorbia neriifolia help control inflammation and immune response in cells.
1 citations
,
October 2025 in “Journal of the American Society of Nephrology” COVID-19 vaccination may cause kidney inflammation, treatable with steroids and Cellcept.
March 2026 in “Journal of Translational Autoimmunity” Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
7 citations
,
April 2021 in “Journal of Pharmacy and Pharmaceutical Sciences” Cetirizine 1% helps hair growth in men with no major side effects, but minoxidil 5% works better.
January 2019 in “Frontiers in neurology” A nutrition program significantly improved a woman's lupus symptoms.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
3 citations
,
June 2019 in “Veterinary record case reports” A dog developed a skin condition called pemphigus foliaceus after taking NexGard, but got better with treatment.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
1 citations
,
May 2021 in “Mayo Clinic Proceedings” A 69-year-old man with sinus infection and fainting spells was diagnosed with a rare kidney disease, treated with steroids and a specific drug, which improved his condition.
2 citations
,
April 2016 in “Más dermatología” The supplement with Serenoa repens and Pygeum africanum significantly increased active hair growth and decreased rest phase hair in post-menopausal women with hair loss, with only mild digestive side effects.
1 citations
,
May 2023 in “Elsevier eBooks” 4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
28 citations
,
May 2023 in “Current Opinion in Colloid & Interface Science”
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
4 citations
,
July 2024 in “Skin Research and Technology”
April 2026 in “Microsystems & Nanoengineering” HA-gel-dex hydrogels help heal wounds and regenerate tissue effectively.
January 2009 in “Yearbook of Dermatology and Dermatologic Surgery” Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.
7 citations
,
January 2025 in “Current Issues in Molecular Biology” Microbial-derived polydeoxyribonucleotide is a better and more sustainable alternative to salmon-based versions for healing and immune support.
May 2025 in “Reactions Weekly”
4 citations
,
February 2022 in “International Journal of Cosmetic Science” Watercress extract helps increase hair growth and thickness by blocking hair loss factors.
January 2026 in “Journal of Dermatology & Dermatologic Surgery” Ruxolitinib helped a man regrow hair after other treatments failed.
July 2026 in “International Journal of Drug Delivery Technology” September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.